Seasonal Influenza Vaccination Status Among Children With Laboratory Evidence of Pandemic H1N1 Infection

2011 ◽  
Vol 30 (7) ◽  
pp. 562-565 ◽  
Author(s):  
Christina A. Nelson ◽  
Eric K. France ◽  
Susan M. Shetterly ◽  
Jason M. Glanz
2014 ◽  
Vol 20 (8) ◽  
pp. 1074-1080 ◽  
Author(s):  
Henning K Olberg ◽  
Rebecca J Cox ◽  
Jane K Nostbakken ◽  
Jan H Aarseth ◽  
Christian A Vedeler ◽  
...  

Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic H1N1 (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic H1N1 vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 – 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) ( p = 0.006), after pandemic H1N1 vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.


2012 ◽  
Vol 26 (9) ◽  
pp. 593-596 ◽  
Author(s):  
Neeraj Narula ◽  
Amit S Dhillon ◽  
Usha Chauhan ◽  
John K Marshall

BACKGROUND Several guidelines recommend influenza vaccination for high-risk patients, including those on immune-suppressing medications (IS).OBJECTIVE: To assess the vaccination status and immunization history of an outpatient inflammatory bowel disease (IBD) population for H1N1 and seasonal influenza.RESULTS: Among 250 patients, 104 (41.6%) had been immunized against H1N1 and 62 (24.8%) against seasonal influenza, and 158 (63.2%) were taking IS (azathioprine, 6-mercaptopurine, infliximab, adalimumab, methotrexate, cyclosporine or prednisone). Among subjects on IS, the presence of comorbidities warranting vaccination was associated with higher likelihood of H1N1 immunization (62.5% versus 35.8%; P=0.022) but not of seasonal influenza vaccination (25.0% versus 17.2%; P=0.392). Among patients without comorbidities warranting vaccination, IS was associated with a decreased likelihood of vaccination against seasonal influenza (17.2% versus 30.7%; P=0.036) but not H1N1 (35.8% versus 41.3%; P=0.46). The frequency of H1N1 vaccination was significantly higher among patients who visited a general practitioner at least once yearly (45.7% versus 20%; P=0.0027), with a similar trend for seasonal influenza vaccination (27.1% versus 12.5%; P=0.073). Among 91 patients on IS who declined vaccination, 39.6% reported fear of immediate side effects, 29.7% reported concerns about developing serious medical complications, 15.4% reported concerns about activating IBD and 15.4% were not aware that vaccination was indicated.CONCLUSIONS: Current strategies for vaccinating IBD patients on IS are inadequate. Primary care provider education, incentive programs and regular primary care contact may improve immunization uptake.


Vaccine ◽  
2011 ◽  
Vol 29 (43) ◽  
pp. 7364-7369 ◽  
Author(s):  
Josette S.Y. Chor ◽  
Surinder K. Pada ◽  
Iain Stephenson ◽  
William B. Goggins ◽  
Paul A. Tambyah ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (5) ◽  
pp. e021144
Author(s):  
Kay Wang ◽  
Tricia Carver ◽  
Sharon Tonner ◽  
Malcolm G Semple ◽  
Alastair D Hay ◽  
...  

IntroductionInfluenza and influenza-like illness (ILI) create considerable burden on healthcare resources each winter. Children with pre-existing conditions such as asthma, diabetes mellitus and cerebral palsy are among those at greatest risk of clinical deterioration from influenza/ILI. The Antibiotics for at Risk CHildren with InfluEnza (ARCHIE) trial aims to determine whether early oral treatment with the antibiotic co-amoxiclav reduces the likelihood of reconsultation due to clinical deterioration in these ‘at risk’ children.Methods and analysisThe ARCHIE trial is a double-blind, parallel, randomised, placebo-controlled trial. ‘At risk’ children aged 6 months to 12 years inclusive who present within the first 5 days of an ILI episode will be randomised to receive a 5-day course of oral co-amoxiclav 400/57 twice daily or placebo. Randomisation will use a non-deterministic minimisation algorithm to balance age and seasonal influenza vaccination status.To detect respiratory virus infections, a nasal swab will be obtained from each participant before commencing study medication. To identify carriage of potential bacterial respiratory pathogens, we will also obtain a throat swab where possible.The primary outcome is reconsultation in any healthcare setting due to clinical deterioration within 28 days of randomisation. We will analyse this outcome using log-binomial regression model adjusted for region, age and seasonal influenza vaccination status.Secondary outcomes include duration of fever, duration of symptoms and adverse events. Continuous outcomes will be compared using regression analysis (or equivalent non-parametric method for non-normal data) adjusting for minimisation variables. Binary outcomes will be compared using χ2/Fisher’s exact test and log-binomial regression.EthicsThe ARCHIE trial has been reviewed and approved by the North West-Liverpool East Research Ethics Committee, Health Research Authority and Medicines and Healthcare Products Regulatory Agency. Our findings will be published in peer-reviewed journals and disseminated via our study website (www.archiestudy.com) and links with relevant charities.Trial registration numbersISRCTN70714783; Pre-results.


Vaccine ◽  
2011 ◽  
Vol 29 (14) ◽  
pp. 2613-2618 ◽  
Author(s):  
Richard Pebody ◽  
Nick Andrews ◽  
Pauline Waight ◽  
Rashmi Malkani ◽  
Christine McCartney ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document